Coste Catherine 4

What Happened

• Catherine Coste, a director of BioLife Solutions (BLFS), was granted 8,170 restricted shares on 2026-02-24. The filing lists the acquisition as an award (grant); no purchase price or immediate cash value is reported.
• This is a compensation/retention award rather than an open-market purchase or sale, so it is not a direct bullish or bearish trade signal.

Key Details

• Transaction date: 2026-02-24; Form 4 filed 2026-02-26 (appears timely).
• Shares granted: 8,170 restricted shares; Price/value: N/A (award).
• Shares owned after transaction: not stated in the filing.
• Footnote: The restricted stock was granted under the BioLife Solutions 2023 Performance Incentive Plan and "fully vests on the first anniversary of the vesting date of January 2, 2026" — i.e., it fully vests on January 2, 2027.
• No 10b5-1 plan, tax withholding, or immediate sale noted in the filing.

Context

• Restricted stock awards are common for director compensation and retention; they typically vest over time and do not indicate an immediate intent to buy or sell stock.
• Because this is an award (not a market transaction), it provides limited information about the director’s market view of the company.